Corrigendum to “Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signaling and the Bid protein and via mitochondrial pathways” [Biochem. Pharmacol. 79 (2010) 361–372, (S0006295209007400), (10.1016/j.bcp.2009.09.007)];Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signaling and the Bid protein and via mitochondrial pathways

Biochemical Pharmacology

Volumn 79, Issue 3, 2010, Pages 361-372

  Bhattacharya, Kaushik ^a   Samanta, Suman K ^a   Tripathi, Rakshamani ^b   Mallick, Asish ^a   Chandra, Sarmila ^c   Pal, Bikas C ^a   Shaha, Chandrima ^b   Mandal, Chitra ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^c Kothari Centre for Gastroenterology   (India)

Author keywords

Bid; Extrinsic apoptosis; Fas FasL; Leukemia; Mahanine

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CD34 ANTIGEN; CYTOCHROME C; FAS ANTIGEN; FAS LIGAND; MAHANINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLSERINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LEUKEMIA CELL; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; MURRAYA; NONHUMAN; OXIDATIVE STRESS; PLANT LEAF; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

EID: 70450224878     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2023.115970     Document Type: Erratum

References (52)

1. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
2. Schulzeosthoff K., Ferrari D., Los M., Wesselbourg S., and Peter M.E. Apoptosis signaling by death receptors. Eur J Biochem 254 (1998) 439-459
3. Waring P., and Müllbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 77 (1999) 312-317
4. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., et al. Human ICE/CED-3 protease nomenclature. Cell 87 (1996) 171
5. Susin S.A., Zamzami N., Castedo M., Daugas E., Wang H.G., Geley S., et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med 186 (1997) 25-37
6. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
7. Nakamura T., Ueda Y., Juan Y., Katsuda S., Takahashi H., and Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 102 (2000) 572-578
8. Oshiro M.M., Landowski H.T., Catlett-Falcone R., Hazlehurst A.L., Huang M., Jove R., et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 7 (2001) 4262-4271
9. Owen-Schaub L. Fas function and tumor progression. Use it and lose it. Cancer Cell 2 (2002) 95-96
10. Owen-Schaub L., Chan H., Cusack J.C., Roth J.A., and Hill L.L. Fas and Fas ligand interactions in malignant disease. Int J Oncol 17 (2000) 5-12
11. Owen-Schaub L., van Golen K.L., Hill L.L., and Price J.E. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 188 (1998) 1717-1723
12. Johnstone R.W., Ruefli A.A., and Lowe S. Apoptosis: linking cancer genetics with chemotherapy. Cell 108 (2002) 153-164
13. Eichhorst B., Goede V., and Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 50 (2009) 171-178
14. Sinha D., Mandal C., and Bhattacharya D.K. Identification of 9-O acetyl sialoglycoconjugates (9-OAcSGs) as biomarkers in childhood acute lymphoblastic leukemia using a lectin, AchatininH, as a probe. Leukemia 13 (1999) 119-125
15. McGregor B.A., Brown A.W., Osswald M.B., and Savona M.R. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol 84 (2009) 228-230
16. Pal S., Ghosh S., Bandyopadhyay S., Mandal C., Bandhyopadhyay S., Kumar Bhattacharya D., et al. Differential expression of 9-O-acetylated sialoglycoconjugates on leukemic blasts: a potential tool for long-term monitoring of children with acute lymphoblastic leukemia. Int J Cancer 111 (2004) 270-277
17. Chowdhury S., Bandyopadhyay S., Mandal C., Chandra S., and Mandal C. Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study. BMC Cancer 8 (2008) 40
18. Breccia M., and Alimena G. Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem. Cardiovasc Hematol Disord Drug Targets 9 (2009) 21-28
19. Dirsch M.V., Antlsperger D., Hentze H., and Vollmar M.A. Ajoene, an experimental anti-leukemic drug: mechanism of cell death. Leukemia 16 (2002) 74-83
20. Hentosh P., and Tibudan M. 2-Chloro-29-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function. Mol Pharmacol 51 (1997) 613-619
21. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2 (2002) 143-148
22. Newman D.J., Cragg G.M., and Snader K.M. The influence of natural products upon drug discovery. Nat Prod Rep 17 (2000) 215-234
23. Ramsewak R.S., Nair M.G., Strasburg G.M., DeWitt D.L., and Nitiss J.L. Biologically active carbazole alkaloids from Murraya koenigii. J Agric Food Chem 47 (1999) 444-447
24. Tachibana Y., Kikuzaki H., Lajis N.H., and Nakatani N. Antioxidative activity of carbazoles from Murraya koenigii leaves. J Agric Food Chem 49 (2001) 5589-5594
25. Nakahara K., Trakoontivakorn G., Alzoreky N.S., Ono H., Onishi-Kameyama M., and Yoshida M. Antimutagenicity of some edible Thai plants, and a bioactive carbazole alkaloid, mahanine, isolated from Micromelum minutum. J Agric Food Chem 50 (2002) 4796-4802
26. Ito C., Itoigawa M., Nakao K., Murata T., Tsuboi M., Kaneda N., et al. Induction of apoptosis by carbazole alkaloids isolated from Murraya koenigii. Phytomedicine 13 (2006) 359-365
27. Roy M.K., Thalang V.N., Trakoontivakorn G., and Nakahara K. Mahanine, a carbazole alkaloid from Micromelum minutum, inhibits cell growth and induces apoptosis in U937 cells through a mitochondrial dependent pathway. Br J Pharmacol 145 (2005) 145-155
28. Roy M.K., Thalang V.N., Trakoontivakorn G., and Nakahara K. Mechanism of mahanine-induced apoptosis in human leukemia cells (HL-60). Biochem Pharmacol 67 (2004) 41-51
29. Sinha S., Pal B.C., Jagadeesh S., Banerjee P.P., Bandyopadhaya A., and Bhattacharya S. Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases. Prostate 66 (2006) 1257-1265
30. Jagadeesh S., Sinha S., Pal B.C., Bhattacharya S., and Banerjee P.P. Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. Biochem Biophys Res Commun 362 (2007) 212-217
31. Yin T., Wu Y.L., Sun H.P., Sun G.L., Du Y.Z., Wang K.K., et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104 (2004) 4219-4225
32. Mandal C., Dutta A., Mallick A., Chandra S., Misra L., Sangwan R.S., et al. Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis 13 (2008) 1450-1464
33. Bandyopadhyay G., Biswas T., Roy K.C., Mandal S., Mandal C., Pal B.C., et al. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood 104 (2004) 2514-2522
34. Papa V., Tazzari P.L., Chiarini F., Cappellini A., Ricci F., Billi A.M., et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22 (2008) 147-160
35. Kuo P.L., Chen C.Y., and Hsu Y.L. Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells. Cancer Res 67 (2007) 7406-7420
36. Lizotte E., Tremblay A., Allen B.G., and Fiset C. Isolation and characterization of subcellular protein fraction from mouse heart. Anal Biochem 345 (2005) 47-54
37. Modzelewski A.R., Davies P., Watkins C.S., Auerbach R., Chang M., and Johnson S.C. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54 (1994) 336-339
38. Roy D., Cai Q., Felty Q., and Narayan S. Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev 10 (2007) 235-257
39. Simon H., Haj-Yehia A., and Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5 (2000) 415-418
40. Zamzami N., Marchetti P., Castedo M., Decaudin D., Macho A., Hirsch T., et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 182 (1995) 367-377
41. Lee D.H., Rhee J.G., and Lee Y.J. Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol 157 (2009) 1189-1202
42. Gong Y., Sohn H., Xue L., Firestone G.L., and Bjeldanes L.F. 3,3′-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res 66 (2006) 4880-4887
43. Ohnuna T., Kobayashi H., and Wang F.S. Anti-MDR ribozyme gene therapy. In: Walther W., and Stein U. (Eds). Methods in molecular medicine, Vol. 35 Gene therapy of cancer: methods and protocols (2000), Humana Press, New Jersey p. 209
44. Weimer L.H., and Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 9 (2009) 69-75
45. Vento S., Cainelli F., and Temesgen Z. Lung infections after cancer chemotherapy. Lancet Oncol 9 (2008) 982-992
46. Alberti C. Cytoskeleton structure and dynamic behaviour: quick excursus from basic molecular mechanisms to some implications in cancer chemotherapy. Eur Rev Med Pharmacol Sci 13 (2009) 13-21
47. Omuro A.M. Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs 9 (2008) 1287-1295
48. Holden J.A. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic. Curr Med Chem Anticancer Agents 1 (2001) 1-25
49. Mandal C, Tringali C, Mondal S, Anastasia L, Chandra S, Bruno V, et al. Down-regulation of membrane-bound Neu3 is negatively correlated with disease progression and associated with apoptosis suppression of lymphoblasts in childhood acute lymphoblastic leukemia. Int J Cancer 2009; [Epub ahead of print] PMID: 19588508.
50. Mondal S, Chandra S, Chitra Mandal. Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia. Leuk Res 2009; [Epub ahead of print] PMID: 19709745.
51. Sieg S., Yildirim Z., Smith D., Kayagaki N., Yagita H., Huang Y., et al. Herpes simplex virus type 2 inhibition of Fas ligand expression. J Virol 70 (1996) 8747-8751
52. Heidari N., Goliaei B., Moghaddam P.R., Rahbar-Roshandel N., and Mahmoudian M. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 18 (2007) 1139-1147